| | Author | Year | Country | Study type | Cancer type | Sample (H/L) | Male | ICIs agents | Line of therapy | Combined medication | Testing time | LMR cut-off | Outcome | Age | Quality evaluation |
| | Man [64] | 2022 | China | R | HCC | 160 (61/99) | 129 | Pembro/Nivo/+Lenva; Sinti/Camre +lenva/Sora | 1st-line | Combined therapy | Baseline | 3.6 | OS, PFS | 58 (26-86) | 7 | | Takashi [65] | 2022 | Japan | R | UC | 149 | 126 | Pembro | 2nd-line or later | NA | Baseline | 1.7 | OS | 72 (67–77) | 6 | | Eisuke [66] | 2022 | Japan | R | Multiple | 61 (32/29) | 49 | Pembro/Nivo/Nivo followed by Pembro | 2nd-line or later | Monotherapy, combined therapy | Baseline | 1.8 or 2.6 | DCR | 71 (46-86) | 6 | | Xueping [67] | 2022 | China | R | LC | 125 (69/56) | 90 | Nivo, Pembro, Atezo | NA | Monotherapy, combined therapy | Baseline | 2.3 | OS | 55 | 6 | | Kosuke [68] | 2022 | Japan | R | RCC | 38 (25/13) | 30 | Nivo | 2nd-line or later | Monotherapy | Baseline | 3.3 | OS, PFS | 68 (44–78) | 5 | | Chan [69] | 2022 | Korea | R | BTC | 68(29/39) | NA | Pembro | 2nd-line or later | Monotherapy | Baseline | 2.5 | OS | 66 | 6 | | Hiroyuki [70] | 2022 | Japan | R | EC | 41(20/21) | 34 | Nivo | 2nd-line or later | Monotherapy | Baseline | 2.2 | OS, PFS, DCR, irAEs | 68 (51-81) | 6 | | Rui [31] | 2022 | China | R | HCC | 110 (79/31) | 100 | Anti-PD-1 | NA | Combined therapy | Posttreatment | 1.8 | OS, PFS | 55 (31-84) | 6 | | Xue [71] | 2022 | China | R | Multiple | 1,047 | 713 | Anti-PD-(L)1 | 1st-line or later | Monotherapy, combined therapy | Baseline | 3.4 | irAEs | 60 | 6 | | Jia [72] | 2022 | China | R | NSCLC | 85(63/22) | 62 | Pembro/Nivo/Sinti/Toripa +/- chemo +/-antiangiogenesis | 1st-line or later | Monotherapy, combined therapy | Baseline | 1.8 | OS, DCR | 66 (47-80) | 7 | | Zhenzhen [73] | 2022 | China | R | NSCLC, SCLC | 66 | 47 | Anti-PD-(L)1 | 1st-line or later | NA | Baseline | 2.1 | PFS | NA | 5 | | Amparo [74] | 2021 | Spain | R | NSCLC | 51(27/24) | 37 | Pembro | 1st-line | Monotherapy | Baseline | 1.9 | OS, PFS | 66 (46–85) | 8 | | Shigeo [75] | 2021 | Japan | R | GC | 51(25/26) | NA | Nivo | 2nd-line or later | Monotherapy | Posttreatment | 3.3 | OS, DCR | 69 (40–84) | 8 | | Yang [76] | 2021 | China | R | GC | 139 (71/68) | 103 | Anti-PD-(L)1+ chemo/anti-VEGF/anti-HER/anti-CTLA-4 | 1st-line or later | Monotherapy, combined therapy | Baseline, posttreatment | 3.5 | OS, PFS, DCR | 60 (51–67) | 7 | | Saeka [77] | 2021 | Japan | R | NSCLC | 171 | 113 | Nivo | 2nd-line or later | Monotherapy | Posttreatment | 2.2 | irAEs | 64 (56–69) | 6 | | Sara [78] | 2021 | Italy | R | RCC | 571 | 402 | Nivo | 2nd-line or late | Monotherapy | Baseline | 2.6 | OS, PFS, DCR | 61 (49–73) | 8 | | Despina [79] | 2021 | USA | R | Multiple | 390 | 275 | Anti-PD-(L)1, anti-CTLA-4 or combination | NA | Monotherapy, combined therapy | Baseline | 1.4 | OS, irAEs | 65 | 6 | | Wei [80] | 2021 | China | R | SCLC | 53 | 34 | Atezo + chemo +/- trilaciclib | 1st-line | Combined therapy | Baseline | 2.7 | OS | NA | 6 | | Saeka [81] | 2021 | Japan | R | NSCLC | 92 | 64 | Pembro | 1st-line or later | Monotherapy | Baseline | 1.5 | irAEs | 60 (34–85) | 6 | | Xiaona [82] | 2021 | China | R | Multiple | 111 (61/50) | 56 | Anti-PD-1 | 1st-line or late | NA | Baseline | 3.2 | OS, PFS, DCR, irAEs | NA | 7 | | Haiping [83] | 2021 | China | R | Multiple | 207 | 156 | Sinti+/- chemo | 1st-, 2nd-, or 3rd-line | Monotherapy, combined therapy | Baseline | 2.8 | OS, PFS | 56 (24-72) | 9 | | DanYun [84] | 2021 | China | R | GC | 53(21/32) | NA | Toripa | 2nd-line or later | Monotherapy | Baseline | 2.8 | OS, PFS | 60 (52–66) | 6 | | Yuki [85] | 2020 | Japan | R | NSCLC | 81 | 37 | Atezo | 2nd-line or later | Monotherapy | Baseline | 1.5 | OS, PFS | 71 (42–84) | 7 | | Sabrina [86] | 2020 | Italy | R | NSCLC | 65(16/49) | 44 | Nivo | 2nd-line or later | NA | Baseline, posttreatment | 1.4 | OS | 68 (39-86) | 6 | | Kazuki [87] | 2020 | Japan | R | NSCLC | 146 | NA | Nivo, Pembro | 1st-line or later | NA | Baseline | 2.1 | PFS | NA | 6 | | Hiroki [88] | 2019 | Japan | R | RCC | 58(21/37) | 45 | Nivo | 2nd-line or later | NA | Baseline | 3.3 | OS, PFS, DCR | 34 | 6 | | Jarrett [89] | 2017 | USA | R | Melanoma | 133 (98/35) | 87 | Pembro | NA | NA | Baseline | 1.7 | OS, PFS | 61 | 8 |
|
|
NA, not available; R, retrospective; NSCLC, non-small cell lung cancer; GC, gastric cancer; RCC, renal cell carcinoma; SCC, small cell lung cancer; UC, urothelial carcinoma; LC, lung cancer; BTC, biliary tract cancer; EC, esophageal cancer; HCC, hepatocellular carcinoma; CRC, colorectal cancer; PLC, primary liver cancer; H/L, LMR high group/ low group; chemo, chemotherapy; ICIs, immune checkpoint inhibitors; Pembro, Pembrolizumab; Nivo, Nivolumab; Atezo, Atezolizumab; Sinti, Sintilimab; Camre, Camrelizumab; Tripri, Triprizumab; Toripa, Toripalimab; Lenva, lenvatinib; Sora, Sorafenib; Apa, apatinib; PD-(L)1, programmed death- (ligands) 1; CTLA-4, cytotoxic T lymphocyte antigen 4; OS, overall survival; PFS, progression free survival; ORR, objective response rate; DCR, disease control rate; irAEs, immune-related adverse events.
|
